Skip to content
OpenCapital
Get started

Viatris VTRS Yupelri ® — Net Sales

Other product segments

Brands
$2.33B+10.2%
Generics
$1.18B+4.5%
Lipitor
$462M+19.1%
Norvasc
$210M+21.9%
Lyrica ®
$120.6M+7.1%
EpiPen® Auto-Injectors
$101.1M+4.6%
Creon ®
$97.4M+18.2%
Viagra ®
$95M-3.6%
Zoloft ®
$72.6M+20.6%
Celebrex ®
$67.1M+5.8%
Effexor ®
$62M+4.6%
Xalabrands
$39.2M+5.7%
Dymista ®
$37.3M-12.9%
Xanax ®
$34.8M+7.7%

Similar metrics at other companies

Theravance Biopharma logo
TBPHYupelri Monotherapy — Revenue
$21.85M+7.0%
AbbVie logo
ABBVUbrelvy — Net revenues
$339M+41.3%
XER
XERSProduct revenue, net — Product revenue, net
$82.45M+42.6%
ANI Pharmaceuticals logo
ANIPILUVIEN and YUTIQ — Net Revenues
$19.26M+19.5%
Pacira BioSciences, Inc. logo
PCRXEXPAREL — Total net product sales
$143.27M+4.9%
CorMedix logo
CRMDProduct sales, net — Total Revenue
$121.92M+212%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$18.49B+81.7%
Enterprise value$31.3B+29.5%
P/S1.3×+0.5×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%—
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity1×+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's yupelri ® — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's yupelri ® — net sales?
Viatris (VTRS) reported yupelri ® — net sales of $62.5M in Q1 2026.
How has Viatris's yupelri ® — net sales changed year-over-year?
Viatris's yupelri ® — net sales increased by 7.2% year-over-year, from $58.3M to $62.5M.
What is the long-term trend for Viatris's yupelri ® — net sales?
Over 4 years (2021 to 2025), Viatris's yupelri ® — net sales has grown at a 13.3% compound annual growth rate (CAGR), from $161.9M to $266.9M.
What does yupelri ® — net sales mean?
This metric represents the total revenue generated from the sale of a specific branded respiratory therapeutic product after accounting for returns, allowances, and rebates. It reflects the market demand and commercial performance of this specialized pharmaceutical asset within the company's broader portfolio. Monitoring this figure helps investors assess the product's lifecycle stage and its contribution to the company's overall top-line growth.